Pharmagossip draws my attention to news in The New York Times about Pfizer’s inhaled insulin product, Exubera:
Pfizer also said today it was postponing the widespread rollout of Exubera, its inhaled insulin, until January — more than six months after federal regulators approved the drug. Exubera, which analysts had predicted would be a blockbuster, now appears to be running into widespread resistance from doctors concerned about its potential risks to the lungs.
Some of that concern was noted here.